Link to Full Article Cambridge, UK., 22 October 2019: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organization funding type 1 diabetes (T1D) research. Under this collaboration, Arecor and JDRF will […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-10-22 04:13:262019-10-25 04:18:22ARECOR AND JDRF SIGN A JOINT RESEARCH, DEVELOPMENT AND COMMERCIALISATION AGREEMENT TO DEVELOP A CO-FORMULATION INSULIN FOR THE TREATMENT OF DIABETES
Link to Full Article MARINA DEL REY, Calif., Oct. 21, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has received a Research and Development (R&D) Tax Incentive cash rebate of USD $1.3 million from the Australian Tax Office based on Armata’s […]
Link to Full Article The publication in the Journal of Global Antimicrobial Resistance concluded that application of a nasal gel formulation of XF-73 in healthy volunteers was safe, well tolerated and generated minimal side effects Treatment with XF-73 was also associated with a rapid reduction in nasal Staphylococcus aureus in all subjects; nasal carriage of […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-10-16 04:22:272019-10-25 04:24:02Positive results published from an independent (US National Institute of Health) XF-73 phase 1 clinical trial in a peer reviewed journal
Link to Full Article HEADLINE DATA READOUT EXPECTED Q4 2019 Cambridge, UK.,4 October 2019: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247. Arecor’s AT247 […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-10-04 04:10:322019-10-25 04:13:12DOSING COMPLETE IN PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN PRODUCT CANDIDATE AT247 FOR DIABETES
Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 30 September, 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced that its American Depositary Shares (“ADS”) have been approved to list on the Nasdaq Capital Market […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-09-30 04:59:062019-10-02 05:04:02AVITA Medical Announces Listing on Nasdaq - Trading of American Depository Shares to begin under the ticker symbol “RCEL” on October 1st
Link to Full Article The European patent office issued patent EP2812424 on 28th August 2019. The patented invention is a multi-well plate containing a scaffold layer which provides a porous three-dimensional network of polymer nanofibres suitable for growing cells in 3D and the process for fabricating the multi-well assay plate. The Electrospinning Company manufactures the Mimetix® range of […]
Link to Full Article Recent journal publications investigate the potential use of the RECELL System to treat multiple dermatological conditions Valencia, Calif., USA, and Melbourne, Australia, 19 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization of innovative therapies leveraging the healing properties of a […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-09-18 05:04:472019-09-19 05:15:38New Data Published in Aesthetic Plastic Surgery Explores the Use of the RECELL System in Combination with Dermabrasion to Treat Acne Scars
Lindsay Cook 18 September 2019 – Dementia costs more than it should. With better, earlier diagnosis and the clever use of technology, the UK could save £100bn in the next 15 years, according to the International Longevity Centre. The alternative: do nothing, put Britain’s health and social care system under intolerable strain and leave hundreds […]
Link to Full Article First RECELL System clinical trial in the U.S. focused on acute soft tissue injuries, defects, and reconstruction; study expected to commence within next 6 months Valencia, Calif., USA, and Melbourne, Australia, 17 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-09-17 04:56:162019-09-19 05:17:33AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction
Link to Full Article Initial clinical emphasis on difficult-to-treat respiratory infections in cystic fibrosis patients MARINA DEL REY, Calif., Sept. 12, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (the “Company” or “Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the Company has developed a new synthetic phage […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-09-12 04:54:002019-09-19 04:55:22Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa
ARECOR AND JDRF SIGN A JOINT RESEARCH, DEVELOPMENT AND COMMERCIALISATION AGREEMENT TO DEVELOP A CO-FORMULATION INSULIN FOR THE TREATMENT OF DIABETES
/in ArecorLink to Full Article Cambridge, UK., 22 October 2019: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organization funding type 1 diabetes (T1D) research. Under this collaboration, Arecor and JDRF will […]
Armata Pharmaceuticals Announces Receipt of $1.3 million R&D Tax Incentive
/in Armata PharmaceuticalsLink to Full Article MARINA DEL REY, Calif., Oct. 21, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has received a Research and Development (R&D) Tax Incentive cash rebate of USD $1.3 million from the Australian Tax Office based on Armata’s […]
Positive results published from an independent (US National Institute of Health) XF-73 phase 1 clinical trial in a peer reviewed journal
/in Destiny PharmaLink to Full Article The publication in the Journal of Global Antimicrobial Resistance concluded that application of a nasal gel formulation of XF-73 in healthy volunteers was safe, well tolerated and generated minimal side effects Treatment with XF-73 was also associated with a rapid reduction in nasal Staphylococcus aureus in all subjects; nasal carriage of […]
DOSING COMPLETE IN PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN PRODUCT CANDIDATE AT247 FOR DIABETES
/in ArecorLink to Full Article HEADLINE DATA READOUT EXPECTED Q4 2019 Cambridge, UK.,4 October 2019: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247. Arecor’s AT247 […]
AVITA Medical Announces Listing on Nasdaq – Trading of American Depository Shares to begin under the ticker symbol “RCEL” on October 1st
/in Avita MedicalLink to Full Article Valencia, Calif., USA, and Melbourne, Australia, 30 September, 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced that its American Depositary Shares (“ADS”) have been approved to list on the Nasdaq Capital Market […]
MULTI-WELL PLATE PATENT GRANTED
/in ElectrospinningLink to Full Article The European patent office issued patent EP2812424 on 28th August 2019. The patented invention is a multi-well plate containing a scaffold layer which provides a porous three-dimensional network of polymer nanofibres suitable for growing cells in 3D and the process for fabricating the multi-well assay plate. The Electrospinning Company manufactures the Mimetix® range of […]
New Data Published in Aesthetic Plastic Surgery Explores the Use of the RECELL System in Combination with Dermabrasion to Treat Acne Scars
/in Avita MedicalLink to Full Article Recent journal publications investigate the potential use of the RECELL System to treat multiple dermatological conditions Valencia, Calif., USA, and Melbourne, Australia, 19 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization of innovative therapies leveraging the healing properties of a […]
Dementia kit: tech leads the charge to protect people’s independence
/in Live Better WithLindsay Cook 18 September 2019 – Dementia costs more than it should. With better, earlier diagnosis and the clever use of technology, the UK could save £100bn in the next 15 years, according to the International Longevity Centre. The alternative: do nothing, put Britain’s health and social care system under intolerable strain and leave hundreds […]
AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction
/in Avita MedicalLink to Full Article First RECELL System clinical trial in the U.S. focused on acute soft tissue injuries, defects, and reconstruction; study expected to commence within next 6 months Valencia, Calif., USA, and Melbourne, Australia, 17 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization […]
Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa
/in Armata PharmaceuticalsLink to Full Article Initial clinical emphasis on difficult-to-treat respiratory infections in cystic fibrosis patients MARINA DEL REY, Calif., Sept. 12, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (the “Company” or “Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the Company has developed a new synthetic phage […]